Tertiary lymphoid structures: Defining immune subtypes and enabling precision immunotherapy in nasopharyngeal carcinoma

Fan Liu; Lei Xiong; Xia Yu; Mingfang Ji

doi:10.1002/ctd2.70111

Clinical and Translational Discovery ›› 2026, Vol. 6 ›› Issue (1) :e70111 DOI: 10.1002/ctd2.70111

INVITED LETTER

Tertiary lymphoid structures: Defining immune subtypes and enabling precision immunotherapy in nasopharyngeal carcinoma

Author information +

History +

PDF

Cite this article

Download citation ▾

Fan Liu, Lei Xiong, Xia Yu, Mingfang Ji. Tertiary lymphoid structures: Defining immune subtypes and enabling precision immunotherapy in nasopharyngeal carcinoma. Clinical and Translational Discovery, 2026, 6(1): e70111 DOI:10.1002/ctd2.70111

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6): 307-325.

[2]	Gago da Graça C, van Baarsen LGM, Mebius RE. Tertiary lymphoid structures: diversity in their development, composition, and role. J Immunol. 2021; 206(2): 273-281.

[3]	Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trend Immunol. 2014; 35(11): 571-580.

[4]	Meylan M, Petitprez F, Becht E, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022; 55(3): 527-541.

[5]	Lee N, Poon I, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53(1): 12-22.

[6]	Chen C, Zhang Y, Wu X, Shen J. The role of tertiary lymphoid structure and B cells in nasopharyngeal carcinoma: based on bioinformatics and experimental verification. Transl Oncol. 2024; 41:101885.

[7]	Almangush A, Ruuskanen M, Hagström J, Kosma VM, Mäkitie AA, Leivo I. Tertiary lymphoid structures in nasopharyngeal carcinoma: a multi-institutional study. Pathol—Res Pract. 2025; 266:155789.

[8]	Zhenfu W, Hong L, Dongdong Q, et al. Nanovaccines fostering tertiary lymphoid structure to attack mimicry nasopharyngeal carcinoma. ACS Nano. 2023; 17(8):7194-7206.

[9]	Vanhersecke L, Brunet M, Guégan JP, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021; 2(8): 794-802.

[10]	Van Rijthoven M, Obahor S, Pagliarulo F, et al. Multi-resolution deep learning characterizes tertiary lymphoid structures and their prognostic relevance in solid tumors. Commun Med. 2024; 4(1): 5.

[11]	Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577(7791): 549-555.

[12]	Gong L, Kwong DLW, Dai W, et al. The stromal and immune landscape of nasopharyngeal carcinoma and its implications for precision medicine targeting the tumor microenvironment. Front Oncol. 2021; 11:744889.

[13]	Liu Y, Ye SY, He S, et al. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nat Commun. 2024; 15(1): 7713.

[14]	Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018; 24(12): 1845-1851.

[15]	Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018; 36(14): 1412-1418.

[16]	Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020; 577(7791): 561-565.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.